Show simple item record

dc.contributor.authorHall, M.
dc.contributor.authorAllan, K.
dc.contributor.authorMichael, A.
dc.contributor.authorClamp, Andrew R
dc.contributor.authorGlasspool, R.
dc.contributor.authorNicum, S.
dc.contributor.authorLord, R.
dc.contributor.authorBanerjee, S. N.
dc.contributor.authorRoche, J.
dc.contributor.authorStobo, J.
dc.contributor.authorGourley, C.
dc.date.accessioned2022-11-30T10:21:27Z
dc.date.available2022-11-30T10:21:27Z
dc.date.issued2022en
dc.identifier.citationHall M, Allan K, Michael A, Clamp AR, Glasspool R, Nicum S, et al. CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301633.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.5577en
dc.identifier.urihttp://hdl.handle.net/10541/625809
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5577en
dc.titleCeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohorten
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMount Vernon Cancer Centre, Northwood, United Kingdomen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record